April: New Drug Approvals by the NMPA - March 2024

• Imported drugs:
•  □　Anakinra injection (Brand name: Kineret) marketed by Swedish Orphan Biovitrum AB (publ) – newly approved for the treatment of Still’s disease.
• □　Spesolimab injection (Brand name: Spevigo) marketed by Boehringer Ingelheim International GmbH
• □　Sugemalimab injection (Brand name: Cejemly) marketed by Pfizer Investment Co., Ltd. - Newly approved in combination with fluoropyrimidine- and platinum-containing chemotherapy as a first-time treatment for unresectable locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma with a PD-L1 expression.
•  
•  
•  
• Domestic drugs:
• □　Atropine sulfate eye drops marketed by Shenyang Sinqi Pharmaceutical Co., Ltd.
• □　Calcium acetate oral solution marketed by Shandong Loncom Pharmaceutical Co., Ltd.
• □　Thiotepa for injection marketed by Jiangsu Hengrui Pharmaceuticals Co., Ltd.
• □　Tunlametinib capsules (Brand name: 科露平 (Ke Lu Ping)) marketed by Kechow Pharma
•  
• (Source: BaiPharm)